on Lisata Therapeutics Inc (isin : US1280583022)
Lisata Therapeutics Inc Gains Positive Outlook in Recent Research Update
On August 18, 2025, First Berlin Equity Research GmbH reaffirmed a "BUY" recommendation for Lisata Therapeutics Inc, maintaining a target price of USD 15.00. This followed the release of the company's H1/25 financial results, which outperformed expectations. Analyst Christian Orquera noted progress in Lisata's pipeline, especially concerning two primary pancreatic cancer trials.
The ASCEND phase 2b trial highlighted positive signals in median progression-free survival and objective response rate for metastatic pancreatic ductal adenocarcinoma. However, the overall survival benefit was slightly less pronounced than earlier data indicated, suggesting a need for further dose optimization.
The iLSTA trial also showed promising preliminary results, enhancing confidence in certepetide's effectiveness, particularly in making non-resectable pancreatic tumors more responsive to immunotherapy. Final results are expected in Q1 2026.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lisata Therapeutics Inc news